Search

Your search keyword '"Jindra, Pavel"' showing total 18 results
Start Over Author "Jindra, Pavel" Journal bone marrow transplantation
18 results on '"Jindra, Pavel"'

1. Current use of fecal microbiota transfer in patients with hematologic diseases: a survey on behalf of the Cellular Therapy and Immunobiology Working Party of the EBMT

Author

Battipaglia, Giorgia, primary, Mooyaart, Jarl E., additional, Meyer, Ralf, additional, Mohty, Mohamad, additional, Sadowska-Klasa, Alicja, additional, Goloshchapov, Oleg, additional, Locatelli, Franco, additional, Styczynski, Jan, additional, Pavlu, Jiri, additional, Dybko, Jaroslaw, additional, Bronin, Gleb, additional, Salmenniemi, Urpu, additional, Jindra, Pavel, additional, Hoogenboom, Jorinde D., additional, Kuball, Jurgen, additional, Ruggeri, Annalisa, additional, and Malard, Florent, additional

Published
2023
Full Text
View/download PDF

2. The European landscape on allogeneic haematopoeietic cell transplantation in Chronic Lymphocytic Leukaemia between 2009 and 2019: a perspective from the Chronic Malignancies Working Party of the EBMT

Author

Tournilhac, Olivier, primary, van Gelder, Michel, additional, Eikema, Dirk-Jan, additional, Zinger, Nienke, additional, Dreger, Peter, additional, Bornhäuser, Martin, additional, Vucinic, Vladan, additional, Scheid, Christof, additional, Cornelissen, Jan J., additional, Schroeder, Thomas, additional, Jindra, Pavel, additional, Sengeloev, Henrik, additional, Nguyen Quoc, Stephanie, additional, Stelljes, Matthias, additional, Blau, Igor Wolfgang, additional, Mayer, Jiri, additional, Paneesha, Shankara, additional, Chevallier, Patrice, additional, Forcade, Edouard, additional, Kröger, Nicolaus, additional, Blaise, Didier, additional, Gribben, John, additional, Nielsen, Bendt, additional, Johansson, Jan-Erik, additional, Kyriakou, Charalampia, additional, Beguin, Yves, additional, Pioltelli, Pietro, additional, Sampol, Antònia, additional, McLornan, Donal P., additional, Schetelig, Johannes, additional, Hayden, Patrick J., additional, and Yakoub-Agha, Ibrahim, additional

Published
2023
Full Text
View/download PDF

3. Autologous versus allogeneic hematopoietic cell transplantation for older patients with acute lymphoblastic leukemia. An analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Author

Giebel, Sebastian, primary, Labopin, Myriam, additional, Houhou, Mohamed, additional, Caillot, Denis, additional, Finke, Jürgen, additional, Blaise, Didier, additional, Fegueux, Nathalie, additional, Ethell, Mark, additional, Cornelissen, Jan J., additional, Forcade, Edouard, additional, Yakoub-Agha, Ibrahim, additional, Lussana, Federico, additional, Maertens, Johan, additional, Bourhis, Jean Henri, additional, Jindra, Pavel, additional, Gorin, Norbert Claude, additional, Nagler, Arnon, additional, and Mohty, Mohamad, additional

Published
2023
Full Text
View/download PDF

4. Correction: Comparison of HLA-mismatched unrelated donor transplantation with post-transplant cyclophosphamide versus HLA-haploidentical transplantation in patients with active acute myeloid leukemia

Author

Baron, Frédéric, primary, Labopin, Myriam, additional, Tischer, Johanna, additional, Ciceri, Fabio, additional, Raiola, Anna Maria, additional, Blaise, Didier, additional, Sica, Simona, additional, Vydra, Jan, additional, Fanin, Renato, additional, Diez-Martin, Jose Luis, additional, Bulabois, Claude Eric, additional, Stölzel, Friedrich, additional, Busca, Alessandro, additional, Jindra, Pavel, additional, Koc, Yener, additional, Chevallier, Patrice, additional, Forcade, Edouard, additional, Rösler, Wolf, additional, Passweg, Jakob, additional, Kulagin, Alexander, additional, Carella, Angelo Michele, additional, Simand, Celestine, additional, Bazarbachi, Ali, additional, Pioltelli, Pietro, additional, Nagler, Arnon, additional, and Mohty, Mohamad, additional

Published
2022
Full Text
View/download PDF

5. Comparison of HLA-mismatched unrelated donor transplantation with post-transplant cyclophosphamide versus HLA-haploidentical transplantation in patients with active acute myeloid leukemia

Author

Baron, Frédéric, primary, Labopin, Myriam, additional, Tischer, Johanna, additional, Ciceri, Fabio, additional, Raiola, Anna Maria, additional, Blaise, Didier, additional, Sica, Simona, additional, Vydra, Jan, additional, Fanin, Renato, additional, Diez-Martin, Jose Luis, additional, Bulabois, Claude Eric, additional, Stölzel, Friedrich, additional, Busca, Alessandro, additional, Jindra, Pavel, additional, Koc, Yener, additional, Chevallier, Patrice, additional, Forcade, Edouard, additional, Rösler, Wolf, additional, Passweg, Jakob, additional, Kulagin, Alexander, additional, Carella, Angelo Michele, additional, Simand, Celestine, additional, Bazarbachi, Ali, additional, Pioltelli, Pietro, additional, Nagler, Arnon, additional, and Mohty, Mohamad, additional

Published
2022
Full Text
View/download PDF

6. Impact of in vivo T-cell depletion in patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplant: a registry study from the Chronic Malignancies Working Party of the EBMT

Author

Forcade, Edouard, primary, Chevret, Sylvie, additional, Finke, Jürgen, additional, Ehninger, Gerhard, additional, Ayuk, Francis, additional, Beelen, Dietrich, additional, Koster, Linda, additional, Ganser, Arnold, additional, Volin, Liisa, additional, Sengeloev, Henrik, additional, Michallet, Mauricette, additional, Tischer, Johanna, additional, Jindra, Pavel, additional, Cascon, Maria Jesús Pascual, additional, Koc, Yener, additional, Arat, Mutlu, additional, Tomaszewska, Agnieszka, additional, Hayden, Patrick, additional, de Witte, Theo, additional, Yakoub-Agha, Ibrahim, additional, Kröger, Nicolaus, additional, and Robin, Marie, additional

Published
2022
Full Text
View/download PDF

7. Natural killer cell alloreactivity in HLA-haploidentical hematopoietic transplantation: a study on behalf of the CTIWP of the EBMT

Author

Ruggeri, Loredana, primary, Vago, Luca, additional, Eikema, Diderik-Jan, additional, de Wreede, Liesbeth C., additional, Ciceri, Fabio, additional, Diaz, Miguel Angel, additional, Locatelli, Franco, additional, Jindra, Pavel, additional, Milone, Giuseppe, additional, Diez-Martin, Josè Luis, additional, Pérez-Simón, Jose Antonio, additional, Merluzzi, Mara, additional, Koster, Linda, additional, van der Werf, Steffie, additional, van Biezen, Anja, additional, Toubert, Antoine, additional, Nagler, Arnon, additional, Chabannon, Christian, additional, Bonini, Chiara, additional, and Velardi, Andrea, additional

Published
2021
Full Text
View/download PDF

8. Second- and third-generation tyrosine kinase inhibitors for Philadelphia-positive adult acute lymphoblastic leukemia relapsing post allogeneic stem cell transplantation—a registry study on behalf of the EBMT Acute Leukemia Working Party

Author

Hirschbühl, Klaus, primary, Labopin, Myriam, additional, Houhou, Mohamed, additional, Gabellier, Ludovic, additional, Labussière-Wallet, Hélène, additional, Lioure, Bruno, additional, Beelen, Dietrich, additional, Cornelissen, Jan, additional, Wulf, Gerald, additional, Jindra, Pavel, additional, Tilly, Hervé, additional, Passweg, Jakob, additional, Niittyvuopio, Riita, additional, Bug, Gesine, additional, Schmid, Christoph, additional, Nagler, Arnon, additional, Giebel, Sebastian, additional, and Mohty, Mohamad, additional

Published
2020
Full Text
View/download PDF

9. Underdiagnosed veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) as a major cause of multi-organ failure in acute leukemia transplant patients: an analysis from the EBMT Acute Leukemia Working Party

Author

Bazarbachi, Abdul Hamid, primary, Al Hamed, Rama, additional, Labopin, Myriam, additional, Halaburda, Kazimierz, additional, Labussiere, Helene, additional, Bernasconi, Paolo, additional, Schroyens, Wilfried, additional, Gandemer, Virginie, additional, Schaap, Nicolaas P. M., additional, Loschi, Michael, additional, Jindra, Pavel, additional, Snowden, John, additional, Wu, Depei, additional, Guffroy, Blandine, additional, Rovira, Montserrat, additional, Chantepie, Sylvain P., additional, Poiré, Xavier, additional, Lopez-Corral, Lucia, additional, Nikolousis, Manos, additional, Pelosini, Matteo, additional, Ciceri, Fabio, additional, Baron, Frederic, additional, Bazarbachi, Ali, additional, Corbacioglu, Selim, additional, Savani, Bipin N., additional, Peric, Zinaida, additional, Nagler, Arnon, additional, Carreras, Enric, additional, and Mohty, Mohamad, additional

Published
2020
Full Text
View/download PDF

10. Incidence and outcome of Kaposi sarcoma after hematopoietic stem cell transplantation: a retrospective analysis and a review of the literature, on behalf of infectious diseases working party of EBMT

Author

Cesaro, Simone, primary, Tridello, Gloria, additional, van der Werf, Steffie, additional, Bader, Peter, additional, Sociè, Gerard, additional, Ljungman, Per, additional, McQuaker, Grant, additional, Giardino, Stefano, additional, Uckan-Cetinkaya, Duygu, additional, Anagnostopoulos, Achilles, additional, Ozdogu, Hakan, additional, Schots, Rik, additional, Jindra, Pavel, additional, Ladetto, Marco, additional, Schroyens, Wilfried, additional, Mikulska, Malgorzata, additional, and Styczynski, Jan, additional

Published
2019
Full Text
View/download PDF

11. Second- and third-generation tyrosine kinase inhibitors for Philadelphia-positive adult acute lymphoblastic leukemia relapsing post allogeneic stem cell transplantation—a registry study on behalf of the EBMT Acute Leukemia Working Party

Author

Hirschbühl, Klaus, Labopin, Myriam, Houhou, Mohamed, Gabellier, Ludovic, Labussière-Wallet, Hélène, Lioure, Bruno, Beelen, Dietrich, Cornelissen, Jan, Wulf, Gerald, Jindra, Pavel, Tilly, Hervé, Passweg, Jakob, Niittyvuopio, Riita, Bug, Gesine, Schmid, Christoph, Nagler, Arnon, Giebel, Sebastian, and Mohty, Mohamad

Abstract

Second- and third-generation tyrosine kinase inhibitors (TKI) play an important role in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL). However, data on feasibility and efficacy of using these drugs for persisting or relapsed Ph + ALL after allogeneic stem cell transplantation (alloSCT) are scarce. Based on the EBMT Acute Leukemia Working Party registry, we evaluated the use of second-/third-generation TKI in 140 patients with Ph + ALL, suffering from measurable residual disease (MRD, n= 6), molecular relapse (MRel, n= 23), or hematological relapse (HRel, n= 111) following alloSCT. Treatment included dasatinib in 104, nilotinib in 18, or ponatinib in 18 patients. Forty-nine patients received TKI monotherapy, while 91 received additional treatment. Toxicity of second-/third-generation TKI post alloSCT was comparable to pretransplant use and could be managed with dose reduction or temporary discontinuation. Response rates were 71% (overall) and 61% (following TKI monotherapy). For the entire cohort, 2- and 5-year overall survival (OS) was 49% and 33%, respectively. OS was comparable among patients treated for persisting MRD/MRel and HRel. Among patients treated with TKI monotherapy, 2- and 5-year OS was 38% and 33%, respectively. The data underscore that second-/third-generation TKI are important compounds for the management of active Ph + ALL post alloSCT.

Published
2021
Full Text
View/download PDF

12. Underdiagnosed veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) as a major cause of multi-organ failure in acute leukemia transplant patients: an analysis from the EBMT Acute Leukemia Working Party

Author

Bazarbachi, Abdul Hamid, Al Hamed, Rama, Labopin, Myriam, Halaburda, Kazimierz, Labussiere, Helene, Bernasconi, Paolo, Schroyens, Wilfried, Gandemer, Virginie, Schaap, Nicolaas P. M., Loschi, Michael, Jindra, Pavel, Snowden, John, Wu, Depei, Guffroy, Blandine, Rovira, Montserrat, Chantepie, Sylvain P., Poiré, Xavier, Lopez-Corral, Lucia, Nikolousis, Manos, Pelosini, Matteo, Ciceri, Fabio, Baron, Frederic, Bazarbachi, Ali, Corbacioglu, Selim, Savani, Bipin N., Peric, Zinaida, Nagler, Arnon, Carreras, Enric, and Mohty, Mohamad

Abstract

Allogeneic hematopoietic cell transplantation (alloHCT) is a complex, potentially fatal therapy featuring a myriad of complications. Triggering event(s) of such complications vary significantly, but often a so-called “multi-organ failure” (MOF) is reported as the leading cause of death. The identification of the exact trigger of MOF is critical towards early and disease-specific intervention to improve outcome. We examined data from 202 alloHCT patients reported to have died of MOF from the EBMT registry aiming to determine their exact cause of death focusing on veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) due to its life-threatening, often difficult to capture yet preventable nature. We identified a total of 70 patients (35%) for whom VOD/SOS could be considered as trigger for MOF and leading cause of death, among which 48 (69%) were previously undiagnosed. Multivariate analysis highlighted history of hepatic comorbidity or gentuzumab use and disease status beyond CR1 as the only significant factors predictive of VOD/SOS incidence (OR = 6.6; p= 0.001 and OR = 3.3; p= 0.004 respectively). VOD/SOS-related MOF was widely under-reported, accounting for 27% of deaths attributed to MOF of unknown origin without a previous VOD/SOS diagnosis. Our results suggest most missed cases developed late VOD/SOS beyond 21 days post-alloHCT, highlighting the importance of the newly revised EBMT criteria.

Published
2021
Full Text
View/download PDF

13. Correction: Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey

Author

Sellner, Leopold, Schetelig, Johannes, Koster, Linda, Choi, Goda, Blaise, Didier, Beelen, Dietrich, Schianca, Fabrizio Carnevale, Passweg, Jakob, Schanz, Urs, Gyan, Emmanuel, Sora, Federica, Kröger, Nicolaus, Wulf, Gerald. G., Van Gorkom, Gwendolyn, Mayer, Jiri, Orvain, Corentin, Bourhis, Jean Henri, Jindra, Pavel, Potter, Victoria, Zallio, Francesco, Vandenberghe, Elisabeth, Robinson, Stephen, Hayden, Patrick J., Yakoub-Agha, Ibrahim, Montoto, Silvia, and Dreger, Peter

Published
2024
Full Text
View/download PDF

14. Audits of collection and apheresis centers: guidelines by the World Marrow Donor Association Working Group Quality and Regulation

Author

Lara-Weisshaupt, Elena, primary, Tistl, Ingrid, additional, Hale, Kuchen, additional, Torosian, Tigran, additional, Schlaphoff, Terry, additional, Manor, Sigal, additional, Jindra, Pavel, additional, Schöffel-Weiß, Sabine, additional, Audat, Françoise, additional, Abress, Linda, additional, and Pingel, Julia, additional

Published
2018
Full Text
View/download PDF

15. Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey

Author

Sellner, Leopold, Schetelig, Johannes, Koster, Linda, Choi, Goda, Blaise, Didier, Beelen, Dietrich, Schianca, Fabrizio Carnevale, Passweg, Jakob, Schanz, Urs, Gyan, Emmanuel, Sora, Federica, Kröger, Nicolaus, Wulf, Gerald. G., Van Gorkom, Gwendolyn, Mayer, Jiri, Orvain, Corentin, Bourhis, Jean Henri, Jindra, Pavel, Potter, Victoria, Zallio, Francesco, Vandenberghe, Elisabeth, Robinson, Stephen, Hayden, Patrick J., Yakoub-Agha, Ibrahim, Montoto, Silvia, and Dreger, Peter

Published
2020
Full Text
View/download PDF

16. Incidence and outcome of Kaposi sarcoma after hematopoietic stem cell transplantation: a retrospective analysis and a review of the literature, on behalf of infectious diseases working party of EBMT

Author

Cesaro, Simone, Tridello, Gloria, van der Werf, Steffie, Bader, Peter, Sociè, Gerard, Ljungman, Per, McQuaker, Grant, Giardino, Stefano, Uckan-Cetinkaya, Duygu, Anagnostopoulos, Achilles, Ozdogu, Hakan, Schots, Rik, Jindra, Pavel, Ladetto, Marco, Schroyens, Wilfried, Mikulska, Malgorzata, and Styczynski, Jan

Abstract

The incidence, the clinical characteristics, and the outcome of Kaposi sarcoma (KS) in patients after hematopoietic stem cell transplantation (HSCT) were assessed. During the period 1987–2018, 13 cases of KS were diagnosed, 3 females and 10 males, median age of 50 years, median time from HSCT of 7 months. KS had an incidence of 0.17% in allogeneic and 0.05% in autologous HSCT. HHV-8 was documented in eight of nine tumor tissue samples assessed. The organ involvement was: skin in nine, lymph nodes in six, oral cavity in four, and visceral in three patients, respectively; seven patients had >1 organ involved. Five patients had immunosuppression withdrawn, whereas four and three patients received radiotherapy and chemotherapy, respectively. Eight patients are alive (median follow-up 48 months, range 5–128), whereas five patients died after a median time of 8 months from the diagnosis of KS. However, no death was caused by KS. We conclude that the incidence of KS after HSCT is very low. Although KS can be managed with the reduction of immunosuppression, visceral forms may require chemotherapy and/or radiotherapy. The low prevalence of KS indicates that screening for HHV-8 serology and surveillance for HHV-8 viremia are not indicated in HSCT patients.

Published
2020
Full Text
View/download PDF

17. Audits of collection and apheresis centers: guidelines by the World Marrow Donor Association Working Group Quality and Regulation

Author

Lara-Weisshaupt, Elena, Tistl, Ingrid, Hale, Kuchen, Torosian, Tigran, Schlaphoff, Terry, Manor, Sigal, Jindra, Pavel, Schöffel-Weiß, Sabine, Audat, Françoise, Abress, Linda, and Pingel, Julia

Abstract

According to the Standards of the World Marrow Donor Association (WMDA), unrelated stem cell donor registries and donor centers are responsible for compliance of their collection and apheresis centers with these Standards. To ensure high stem cell product quality and high standards for safety and satisfaction of voluntary unrelated stem cell donors, we here present guidelines for audits of collection and apheresis centers that can be used by new and established donor registries, as well as by collection centers in preparation of audits. We define the general requirements and recommendations for collaboration with the collection and apheresis centers and define critical procedures for the collection of the stem cell product, such as information session, medical assessment, product collection, quality controls, product handover for transportation, and donor follow-up. The specific guidelines are accompanied by detailed checklists and forms that can be found in Supplementary Information and may be used during an initial or follow-up on-site or paper-based audit.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results